Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
A new study involving theoretical and experimental assays provides proof of concept of a fully biological self-restoring system that automatically detects and terminates cardiac arrhythmias.
The notion that atherosclerosis can be prevented or mitigated by vaccination is now moving towards clinical trials. This strategy is based on the existence of autoimmunity to LDL, the cholesterol-carrying particles that accumulate in arteries. In this Comment, we discuss the underlying concepts, research basis and challenges for the development of a vaccine against atherosclerosis.
In patients with COVID-19, myocardial injury is prevalent and is associated with an adverse prognosis and increased mortality, according to two retrospective cohort studies from China and the USA.
In a new cross-trial analysis of patients with heart failure with reduced ejection fraction, researchers predict that a comprehensive strategy combining several pharmacological approaches reduces hospitalization and mortality compared with conventional therapy.
A new biomimetic drug delivery system consisting of nanoparticles that are coated with macrophage membrane and responsive to reactive oxygen species enables targeted pharmacotherapy for atherosclerosis in mice while also suppressing local inflammation by sequestering inflammatory factors.
Similar rates of infection and device-related deaths were observed between patients who received a recycled cardiac device and patients who received a new device.
According to five new studies, therapy with angiotensin-converting enzyme (ACE) inhibitors or angiotensin-receptor blockers (ARBs) is not associated with an increased risk of infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or with an increased risk of severe disease or in-hospital death among patients with COVID-19.
Individuals with obesity have an increased prevalence of the Bacteroides 2 enterotype, which is associated with systemic inflammation and disease. However, statin therapy is associated with a reduced prevalence of this dysbiosis in individuals with obesity.
Using cardiac MRI-derived structural and functional data from UK Biobank participants, Aragam and colleagues identified novel variants at 45 genetic loci that associate with risk of dilated cardiomyopathy.
According to findings from the POPular AGE trial, clopidogrel treatment is associated with a lower bleeding risk compared with ticagrelor in older patients with non-ST-elevation acute coronary syndrome.
A new study shows that regulatory T cells have essential roles in atherosclerotic plaque regression by promoting the resolution of plaque inflammation through suppression of macrophage and T cell pro-inflammatory responses and induction of a pro-resolving macrophage phenotype.
An adverse childhood family environment is associated with an increased rate of cardiovascular disease and death in middle age, according to a longitudinal cohort study.
An ‘off-the-shelf’, cell-free, artificial cardiac patch has been created that is easy to store and improves outcomes in rat and pig models of myocardial infarction.
Apixaban therapy is as effective as low-molecular-weight heparin therapy for the prevention of recurrence of venous thromboembolism in patients with cancer, with no increase in major bleeding events, according to findings from the Caravaggio trial.
Findings from the VOYAGER PAD study show that adding rivaroxaban to standard aspirin therapy can reduce ischaemic risk in patients with peripheral artery disease who have undergone lower-extremity revascularization.